Liquidia Corporation LQDA
57.41 USD -0.71 (-1.22%)
Regular-session close
56.92 -0.49 -0.85%
After hours · Nov 13, 6:58 PM ET
57.00 Day range 59.49
25.91 52-week range 91.03
- YTD
- +66.45%
- 1 year
- +113.10%
News
seekingalpha.com Liquidia: Yutrepia's PAH Franchise Has Room To Grow Liquidia kept the right to market YUTREPIA for PAH after the settlement with United Therapeutics. This settlement limits YUTREPIA's potential in PH-ILD, but since it can still be sold to patients…
benzinga.com HC Wainwright & Co. Assumes Liquidia at Buy, Announces Price Target of $76 HC Wainwright & Co. analyst Matthew Caufield assumes Liquidia (NASDAQ:LQDA) with a Buy rating and announces Price Target of $76.
zacks.com LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales Liquidia's Q3 earnings and revenues beat estimates as Yutrepia sales surge, while strong PAH demand and pipeline investments support growth.
zacks.com LQDA Q3 Earnings Call Highlights Growth and Post-Settlement Outlook Liquidia reports surging YUTREPIA sales, record October shipments and expanding PAH adoption amid post-settlement market changes and referral disruptions.
benzinga.com Needham Maintains Buy on Liquidia, Raises Price Target to $66 Needham analyst Serge Belanger maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price target from $58 to $66.
defenseworld.net Liquidia (NASDAQ:LQDA) Stock Price Breaks Above Fifty Day Moving Average Following Weak Earnings Liquidia Corporation (NASDAQ: LQDA - Get Free Report) shares crossed above its 50 day moving average during trading on Tuesday following a better than expected earnings announcement. The stock has a…
marketbeat.com Liquidia Q3 Earnings Call Highlights Liquidia NASDAQ: LQDA reported a 31% sequential increase in third-quarter YUTREPIA sales as the company sought to reassure investors that its pulmonary arterial hypertension business can continue…
seekingalpha.com Liquidia Corporation (LQDA) Q3 2026 Earnings Call Transcript Liquidia Corporation (LQDA) Q3 2026 Earnings Call Transcript
benzinga.com BTIG Maintains Buy on Liquidia, Raises Price Target to $87 BTIG analyst Julian Harrison maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price target from $70 to $87.
benzinga.com Liquidia Q3 2026 Earnings Call Transcript Liquidia (NASDAQ:LQDA) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time…- benzinga.com UPDATE: Liquidia Q3 Adj. EPS $1.71 Beats $0.96 Estimate, Sales $225.000M Beat $214.182M Estimate (Adj EPS Excludes Litigation Settlement) Liquidia (NASDAQ:LQDA) reported quarterly earnings of $1.71 per share which beat the analyst consensus estimate of $0.96 by 78.13 percent. This is a 4375 percent increase over losses of $(0.04) per…
zacks.com Liquidia Corporation (LQDA) Q3 Earnings and Revenues Beat Estimates Liquidia Corporation (LQDA) came out with quarterly earnings of $0.8 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to a loss of $0.04 per share a year ago.
globenewswire.com Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference MORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta, Chief Operating Officer and…
benzinga.com Liquidia Q3 EPS $(2.64) Misses $0.94 Estimate, Sales $225.300M Beat $214.182M Estimate Liquidia (NASDAQ:LQDA) reported quarterly losses of $(2.64) per share which missed the analyst consensus estimate of $0.94 by 380.85 percent. This is a 6500 percent decrease over losses of $(0.04)…
globenewswire.com Liquidia Corporation Reports Third Quarter 2026 Financial Results MORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with…
benzinga.com Petrobras, TransDigm On Deck Tuesday As Oil Profits, Aerospace Demand Face Test Petroleo Brasileiro headlines Tuesday’s reports, with investors weighing whether strong production and operating performance can offset pressure on energy prices. TransDigm Group, Honda Motor, Sea,…
globenewswire.com Liquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026 MORRISVILLE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with…
zacks.com Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect? LQDA's Q3 results will spotlight the impact of its legal settlement with UTHR, cash flow pressures, profitability prospects and pipeline progress.
zacks.com Liquidia Corporation (LQDA) Earnings Expected to Grow: Should You Buy? Liquidia Corporation (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
benzinga.com Range Resources, Xtend AI Robotics, Oruka Therapeutics And Other Big Stocks Moving Higher On Monday U.S. stocks rose; Dow gained 350 points. Range Resources jumped 15% on EQT acquisition, while Surgery Partners and others posted sharp gains.
newsfilecorp.com Liquidia Corporation Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money on Your LQDA Investments New York, New York--(Newsfile Corp. - October 21, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:…- benzinga.com HC Wainwright & Co. Maintains Buy on Liquidia, Raises Price Target to $65 HC Wainwright & Co. analyst Andrew S. Fein maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price target from $58 to $65.
zacks.com LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.
proactiveinvestors.com Liquidia shares surge 25% as settlement ends United Therapeutics litigation Liquidia Corporation (NASDAQ:LQDA), the biopharmaceutical company, surged 25% to $33.47 after settling all six pending lawsuits with United Therapeutics Corporation (NASDAQ:UTHR), ending years of…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers MaxCyte (NASDAQ:MXCT) shares rose 34.5% to $1.3 during Wednesday's regular session. The company's market cap stands at $102.6 million. Liquidia (NASDAQ:LQDA) stock moved upwards by 26.29% to…
benzinga.com Nasdaq Dips Over 400 Points; Bank of America Shares Tumble After Q3 Results US stocks fell Wednesday as Nasdaq dropped 1.54% and Dow 0.35%; Bank of America sank 5% after weak results, while oil rose and inflation topped forecasts.
247wallst.com United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42% A patent court ruling wiped out nearly half of Liquidia's stock value in a single day, and the settlement that followed cost the company almost every dollar it had in the bank.- benzinga.com Wells Fargo Maintains Equal-Weight on Liquidia, Raises Price Target to $33 Wells Fargo analyst Benjamin Burnett maintains Liquidia (NASDAQ:LQDA) with a Equal-Weight and raises the price target from $30 to $33.
benzinga.com Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday U.S. stocks were mostly lower, with the Nasdaq Composite falling around 200 points on Wednesday.
benzinga.com Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday U.S. stocks mostly fell, but Bending Spoons surged 40% after Berkshire’s $330M investment. Liquidia and Verastem also posted strong gains.
barrons.com This Biotech Stock Surges 37% on Patent Settlement. ‘Better Than the Best-Case Scenario. Liquidia surges after reaching a $380.7 million settlement with United Therapeutics resolving patent disputes for its lung disease drug.
benzinga.com Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain Even as September Inflation Report Comes In Hotter Than Expected— ASML, AZZ, GME in Focus (UPDATED) U.S. stock futures were higher on Wednesday, as the Dow Jones, S&P 500 and Nasdaq 100 indices rose, following Tuesday's lower close.
benzinga.com This Albemarle Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday Analysts upgraded ALB, LQDA, WY, RAL, setting or revising price targets to $130, $70, $25, $88.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Liquidia (NASDAQ:LQDA) shares moved upwards by 41.0% to $37.8 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.4 billion. Greenland Mines…
benzinga.com Liquidia Settles Bitter Fight With United Therapeutics Liquidia (LQDA) stock jumped 40% after settling all lawsuit battles with United Therapeutics for $380.7M. YUTREPIA PAH sales continue.
benzinga.com Needham Maintains Buy on Liquidia, Lowers Price Target to $58 Needham analyst Serge Belanger maintains Liquidia (NASDAQ:LQDA) with a Buy and lowers the price target from $72 to $58.
benzinga.com Why Enovix Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket Enovix jumps 6.8% after securing a 100,000-unit battery order from a multinational drone maker, with deliveries planned for H1 2027.
benzinga.com Liquidia Corporation Stock Is Trending In After-Hours Following United Therapeutics Settlement: What You Should Know Liquidia shares surged 42.48% in after-hours trading after settling all pending litigation with United Therapeutics over YUTREPIA patents.
benzinga.com Liquidia Will Continue To Advance YUTREPIA And L606 Clinical Programs As Previously Outlined; Liquidia Has Submitted A Supplement To Remove The PH-ILD Indication From YUTREPIA’ ’s Label And No Longer Promotes It For PH-ILD The settlement follows the September 30, 2026, ruling by the U.S. District Court for the District of Delaware (the Court) that claims 1 and 14 of U.S. Patent No. 11,826,327 (the ’327 patent) are…- benzinga.com Liquidia Enters Into A Global Settlement Agreement With United Therapeutics That Resolves All Pending Litigation Between The Companies; Settlement Fully Resolves Six Ongoing Lawsuits Between Liquidia And United Therapeutics; Liquidia To Pay Net $380.70M In Installments In 2026 And 2027; Liquidia Will Make A Net Payment To UTHR Of $175M Within 30 Business Days Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced…
globenewswire.com Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH MORRISVILLE, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with…
gurufocus.com Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky Liquidia Corporation (LQDA) Securities Investigation Notice - Levi and KorsinskyPR NewswireNEW YORK, Oct. 12, 2026Liquidia shareholders took a roughly 57% loss af
benzinga.com First Tracks Biotherapeutics, C3.ai, CCC Intelligent Solutions And Other Big Stocks Moving Higher On Monday U.S. stocks mixed; First Tracks Biotherapeutics surged 18% on positive celiac trial results, while C3.ai, Liquidia and others also gained.- benzinga.com Wells Fargo Downgrades Liquidia to Equal-Weight, Lowers Price Target to $30 Wells Fargo analyst Benjamin Burnett downgrades Liquidia (NASDAQ:LQDA) from Overweight to Equal-Weight and lowers the price target from $108 to $30.
- benzinga.com HC Wainwright & Co. Maintains Buy on Liquidia, Lowers Price Target to $58 HC Wainwright & Co. analyst Andrew S. Fein maintains Liquidia (NASDAQ:LQDA) with a Buy and lowers the price target from $130 to $58.
benzinga.com Apple To $355? Here Are 10 Top Analyst Forecasts For Thursday Analysts raised targets for HPE, Phillips 66, Micron and AEON; cut targets for Liquidia, Apple and Zions.
benzinga.com Raymond James Downgrades Liquidia to Outperform, Lowers Price Target to $53 Raymond James analyst Ryan Deschner downgrades Liquidia (NASDAQ:LQDA) from Strong Buy to Outperform and lowers the price target from $106 to $53.
benzinga.com Liquidia Stock Extends Slide Following US Court Ruling in Patent Dispute Shares of Liquidia Corp (NASDAQ: LQDA) are sliding Thursday morning, extending a sell-off triggered by an adverse federal court patent ruling in its ongoing legal dispute with rival United…
benzinga.com This ExxonMobil Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday Analysts downgraded Liquidia, Sigma Lithium, ExxonMobil, Ormat Technologies and Ethos Technologies, with updated or reduced price targets.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers DataMEDS AI (NASDAQ:MEDS) stock moved upwards by 39.4% to $4.42 during Thursday's pre-market session. The company's market cap stands at $10.1 million. Stablecoin Development (AMEX:SDEV)…